Pfizer's dividend yield has risen above 6%, notably higher than peers, due to a share price decline despite steady dividends. While the company maintains a strong earnings buffer and CEO Albert Bourla has assured the dividend will hold, free cash flow coverage is tight and Pfizer carries significant debt. The firm faces challenges from declining COVID drug revenues and patent expirations but expects cost savings and new drug growth to support dividends until around 2029. Investors receive a high yield as compensation for waiting through this period of slow growth and risk.
Pfizer's stock trades at USD 28.23 on Pluang as of Oct 10, 2026 01:02 WIB, close to its 52-week high of USD 29.02, while offering a dividend yield of 6.18%, which stands out in the health sector. Despite a 1-day gain of 1.47%, Pluang users are predominantly selling Pfizer shares, with 89% of order activity on the platform being sell orders. This contrasts with the stock's 52-week low of USD 23.67, highlighting Pfizer's current valuation near its upper range amid dividend concerns.
Moderna's stock rose 5% following its addition to the NASDAQ 100, driven by automatic fund buying linked to the index inclusion. This marks a shift from its COVID-19 vaccine identity to a growth biotech with a promising oncology pipeline, highlighted...
Cantor Fitzgerald increased price targets for four major pharmaceutical companies: Eli Lilly, AbbVie, Merck, and Pfizer, while maintaining their current ratings. Eli Lilly and AbbVie received Overweight ratings with higher targets, reflecting stronge...
Four well-known companies—Pfizer, UPS, Kraft Heinz, and Ford—offer dividend yields above 5%, but their earnings, cash flow, and debt levels raise doubts about the sustainability of these payouts. Pfizer and UPS pay dividends exceeding their GAAP earn...
Pfizer expects its stronger non-COVID business to more than offset lower revenue from COVID-related products, though full-year revenue guidance still indicates a decline. The company plans to achieve $2.7 billion in cost savings through 2029, which c...
Pfizer offers a dividend yield of 6.24%, much higher than Johnson & Johnson's 2.07%, but Pfizer's payout is frozen and not fully covered by free cash flow, with rising debt and a recent $4.3 billion write-down signaling risk. Johnson & Johnson, despi...
